1. Andrew E, Nilsen A, Thune P, Wilk (1981) Photochemotherapy in psoriasis. Clinical response and 8-MOP plasma concentrations at two levels. Clin Exp Dermatol 6: 591?600
2. Aubin F, Manteaux A (1990) Mécanismes de photoréaction des psoralènes. Ann Dermatol Venereol 117: 931?936
3. Brodie RR, Irons SR, Chasseaud LF, Taylor T, Morris GR, Baker JM, Forlot P (1989) Bioavailability of 5-methoxypsoralen (5-MOP) from formulations containing the micronized and unmicronized drug. In: Fitzpatrick TB, Forlot P, Pathak MA, Urbach F (eds) Psoralens: past, present, and future of photochemoprotection and other biological activities. John Libbey Eurotext, Paris, pp 263?267
4. Calzavara-Pinton P, Ortel B, Carlino A, De Panfilis G (1992) A Reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1: 46?51
5. George SA, Ferguson J (1992) Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects. Photodermatol Photoimmunol Photomed 9: 33?35